The randomized, double-blind, placebo-controlled study will mainly evaluate the safety and local tolerability of TIR-C applied to the skin in adults with atopic dermatitis. Secondary objectives include measuring how much of the drug reaches the bloodstream. Exploratory endpoints will give a first indication of efficacy using established measures, including the Eczema Area and Severity Index (EASI), the validated Investigator Global Assessment (vIGA), and patient-reported itch.

The first cohort comprises eight participants enrolled at the Swedish clinic where the study is being conducted. Safety data will be reviewed once all participants in the cohort have completed treatment, before the study moves on to the next cohort.

TIR-C is an oligonucleotide-based treatment applied to the skin. It is designed to regulate the immune system and target the underlying mechanisms of the disease rather than only relieve symptoms. Pharmability was formerly known as TIRmed Pharma.

“Dosing the first patient in our Phase Ib study marks Pharmability’s step into clinical development,” said CEO Leo Holmgren.